Active Melanoma Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Melanoma Clinical Trial?

• Find Trials That Fit — Browse recruiting Melanoma trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Melanoma type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Melanoma Clinical Trial FAQ

Do I need a BRAF mutation to join a melanoma clinical trial?

Not all trials require a BRAF mutation, but those testing BRAF/MEK inhibitors (dabrafenib + trametinib, vemurafenib + cobimetinib) do require a BRAF V600E or V600K mutation. Immunotherapy trials generally enroll BRAF-mutated and BRAF wild-type patients alike. Molecular testing of your tumor is standard practice for melanoma and will clarify which trials you qualify for.

Are there melanoma trials for patients with stage III (regional) disease?

Yes. Stage III melanoma trials — particularly adjuvant trials after surgery — are very active. Approved adjuvant therapies (pembrolizumab, nivolumab, dabrafenib + trametinib) showed benefit in trials, and new adjuvant approaches are being studied. If your melanoma was resected and you are at high risk of recurrence, ask about adjuvant clinical trial options.

What is TIL (tumor-infiltrating lymphocyte) therapy, and is there a melanoma trial for it?

TIL therapy is a type of adoptive cell therapy where immune cells are extracted from your tumor, expanded in a lab, and infused back into your body. Lifileucel (Amtagvi) received FDA approval for advanced melanoma in 2024. Clinical trials are now testing next-generation TIL therapies, combinations with checkpoint inhibitors, and TIL approaches for other tumor types.

Can melanoma patients who progressed on checkpoint immunotherapy join trials?

Yes — this is an active area of research. Trials are testing novel agents (LAG-3 inhibitors, TIGIT inhibitors, bispecific antibodies), TIL therapy, and combination strategies specifically for patients who progressed on anti-PD-1 therapy. Prior immunotherapy history is actually an eligibility criterion in many trials, so these patients are actively sought.

How does Trialify help melanoma patients find trials?

Enter your melanoma stage, BRAF status, prior treatments, and location. Trialify searches ClinicalTrials.gov and translates the eligibility criteria into plain language questions. You get a match assessment and a printable doctor summary — all without creating an account or sharing personal health information.

Explore Other Cancer Trial Guides

• Lung Cancer — Lung cancer is the leading cause of cancer-related death worldwide. Recruiting clinical trials are testing new immunotherapies, targeted therapies, and combination regimens for NSCLC and SCLC patients.
• Kidney Cancer — Kidney cancer trials are evaluating immunotherapy combinations, HIF-2α inhibitors like belzutifan, and novel TKI regimens for clear cell and non-clear cell renal cell carcinoma.
• Bladder Cancer — Bladder cancer trials are evaluating checkpoint immunotherapy, enfortumab vedotin-based combinations, and FGFR inhibitors for both non-muscle-invasive and muscle-invasive disease.
• Lymphoma — Lymphoma trials are studying CAR-T cell therapies, bispecific antibodies, and targeted agents for both Hodgkin and non-Hodgkin subtypes — including diffuse large B-cell, follicular, and mantle cell lymphoma.